Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pro-survival Function of Akt/Protein Kinase B in Prostate Cancer Cells
Thakkar, H., Chen, X., Tyan, F., Gim, S., Robinson, H. M., Lee, C., Pandey, S., Nwokorie, C., Onwudiwe, N. C., & Srivastava, R. K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103321200 · Cited by 117
RetractedIdentification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900 · cited 1×
“Apo2 ligand/ TNF-Related Apoptosis Inducing Ligand (Apo2L/ TRAIL) is a TNF-a-like protein which induces apoptosis against a wide range of neoplastic cells, but spares normal tissues (Ashkenazi et al., 1999; Pitti et al., 1996; Wiley et al., 1995).”
BackgroundWang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
Lin, Y.-Z., Yao, S., Veach, R. A., Torgerson, T. R., & Hawiger, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.24.14255 · Cited by 918
Chu, Z.-L., McKinsey, T. A., Liu, L., Gentry, J. J., Malim, M. H., & Ballard, D. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10057 · Cited by 872 · cited 1×
“…anti-apoptotic proteins in MM cells We next examined the effects of IGF-1 and IL-6 on expression of intracellular anti-apoptotic proteins which are downstream targets of NF-kB in other tissue models, e.g. cIAP-2, cIAP-1 (Chu et al., 1997; Wang et al., 1998) and A1/Bfl-1 (Wang et al., 1999).”
BackgroundInduction of NF-κB by the Akt/PKB kinase
Kane, L. P., Shapiro, V. S., Stokoe, D., & Weiss, A. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80265-6 · Cited by 846
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Self-citationWang, C.-Y., Guttridge, D. C., Mayo, M. W., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5923 · Cited by 590
Cited by
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationMesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine
Murphy, M. B., Moncivais, K., & Caplan, A. I. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.94 · Cited by 1,231
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Self-citationMolecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
Self-citationChauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
“As in our prior studies (Chauhan and Anderson, 2003; Mitsiades et al., 2002a ), both rhIL-6 and rhIGF-I block Dex-induced decreases in MM.1S cell viability.”
ResultSelf-citationJung, Y.-J., Isaacs, J. S., Lee, S., Trepel, J., & Neckers, L. (2003) · The FASEB Journal · doi:10.1096/fj.03-0329fje · Cited by 679
Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Akiyama, M., Hideshima, T., Chauhan, D., Joseph, M., Libermann, T. A., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00050-9 · Cited by 614
Self-citationAdvances in biology of multiple myeloma: clinical applications
Hideshima, T., Bergsagel, P. L., Kuehl, W. M., & Anderson, K. C. (2004) · Blood · doi:10.1182/blood-2004-01-0037 · Cited by 582
Self-citationMoreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Rème, T., Lugagne, C., Moine, P., Rossi, J.-F., Klein, B., & Tarte, K. (2004) · Blood · doi:10.1182/blood-2003-06-1984 · Cited by 558
Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536759100 · Cited by 531
Self-citationMolecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Self-citationHideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., Podar, K., Munshi, N. C., Chauhan, D., Richardson, P. G., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3434 · Cited by 422
Self-citationApoptosis-based therapies for hematologic malignancies
Reed, J. C., & Pellecchia, M. (2005) · Blood · doi:10.1182/blood-2004-07-2761 · Cited by 402
The Role of Curcumin in Aging and Senescence: Molecular Mechanisms
Zia, A., Farkhondeh, T., Pourbagher-Shahri, A. M., & Samarghandian, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111119 · Cited by 378
Shi, Y., Yan, H., Frost, P., Gera, J., & Lichtenstein, A. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0068 · Cited by 368
RetractedBortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N. C., Richardson, P. G., Carrasco, R. D., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199604 · Cited by 363
Self-citationMartelli, A. M., Nyåkern, M., Tabellini, G., Bortul, R., Tazzari, P. L., Evangelisti, C., & Cocco, L. (2006) · Leukemia · doi:10.1038/sj.leu.2404245 · Cited by 342
Antimyeloma activity of heat shock protein-90 inhibition
Mitsiades, C. S. (2005) · Blood · doi:10.1182/blood-2005-03-1158 · Cited by 319
Self-citationMcMillin, D. W., Delmore, J., Weisberg, E., Negri, J. M., Geer, D. C., Klippel, S., Mitsiades, N., Schlossman, R. L., Munshi, N. C., Kung, A. L., et al. (2010) · Nature Medicine · doi:10.1038/nm.2112 · Cited by 315
Self-citationTowards targeting of shared mechanisms of cancer metastasis and therapy resistance
Weiss, F., Lauffenburger, D., & Friedl, P. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00427-0 · Cited by 293
Pathogenesis beyond the cancer clone(s) in multiple myeloma
Bianchi, G., & Munshi, N. C. (2015) · Blood · doi:10.1182/blood-2014-11-568881 · Cited by 288
Self-citationThe case for survivin as a regulator of microtubule dynamics and cell-death decisions
Altieri, D. C. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.08.015 · Cited by 284
The growing challenge of obesity and cancer: an inflammatory issue
Harvey, A. E., Lashinger, L. M., & Hursting, S. D. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06096.x · Cited by 272
Hideshima, T., Richardson, P. G., & Anderson, K. C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0433 · Cited by 265
Self-citationAnderson, K. C., & Carrasco, R. D. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130249 · Cited by 258
Self-citationSurvival and Proliferation Factors of Normal and Malignant Plasma Cells
Klein, B., Tarte, K., Jourdan, M., Mathouk, K., Moreaux, J., Jourdan, E., Legouffe, E., Vos, J. D., & Rossic, J. F. (2003) · International Journal of Hematology · doi:10.1007/bf02983377 · Cited by 215
Lin, M.-T., Chang, C.-C., Chen, S.-T., Chang, H.-L., Su, J.-L., Chau, Y.-P., & Kuo, M.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402305200 · Cited by 194
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
Raje, N., Kumar, S., Hideshima, T., Ishitsuka, K., Chauhan, D., Mitsiades, C., Podar, K., Le Gouill, S., Richardson, P., Munshi, N. C., et al. (2004) · Blood · doi:10.1182/blood-2004-06-2281 · Cited by 187
Self-citationKiziltepe, T., Hideshima, T., Catley, L., Raje, N., Yasui, H., Shiraishi, N., Okawa, Y., Ikeda, H., Vallet, S., Pozzi, S., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0010 · Cited by 180
Self-citationInvolvement of the nuclear factor-κB pathway in the pathogenesis of endometriosis
González-Ramos, R., Van Langendonckt, A., Defrère, S., Lousse, J.-C., Colette, S., Devoto, L., & Donnez, J. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.01.013 · Cited by 179
Insulin/IGF-1 paradox of aging: Regulation via AKT/IKK/NF-κB signaling
Salminen, A., & Kaarniranta, K. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2009.10.006 · Cited by 177
Hideshima, T., Chauhan, D., Hayashi, T., Akiyama, M., Mitsiades, N., Mitsiades, C., Podar, K., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207170 · Cited by 164
“…we have demonstrated that PS-341 induces activation of caspase-8 and caspase-9, followed by caspase-3 cleavage (Hideshima et al., 2001c, 2003b; Mitsiades et al., 2002b), we next hypothesized that the cytoplasmic domain of gp130, like other proteins, might also be cleaved or downregulated via…”
BackgroundMethodResultInfluentialSelf-citationLopes, R. B., Gangeswaran, R., McNeish, I. A., Wang, Y., & Lemoine, N. R. (2007) · International Journal of Cancer · doi:10.1002/ijc.22554 · Cited by 158
The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
Vrábel, D., Pour, L., & Ševčíková, S. (2019) · Blood Reviews · doi:10.1016/j.blre.2018.11.003 · Cited by 123
Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments
Hu, J., & Hu, W.-X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.020 · Cited by 84
Fabre, C., Mimura, N., Bobb, K., Kong, S.-Y., Gorgun, G., Cirstea, D., Hu, Y., Minami, J., Ohguchi, H., Zhang, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0779 · Cited by 82
“Since IL-6 and IGF-I are major growth and/or survival factors in the BM milieu (8, 23-28), we examined their effect on PBS-1086-induced apoptosis.”
BackgroundSelf-citationSignaling Pathway Mediating Myeloma Cell Growth and Survival
Hideshima, T., & Anderson, K. C. (2021) · Cancers · doi:10.3390/cancers13020216 · Cited by 70
“In MM, PI3K-Akt signaling is one of the most complex signaling pathways since it is activated by many cytokines including IL-6, IGF-1, VEGF, CXCL12, and BAFF [1,11]; it has numerous downstream targets mediating diverse biological activities.”
BackgroundInfluentialSelf-citationBioprinting and organ-on-chip applications towards personalized medicine for bone diseases
Arrigoni, C., Gilardi, M., Bersini, S., Candrian, C., & Moretti, M. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9741-5 · Cited by 68
Maiso, P., Mogollón, P., Ocio, E. M., & Garayoa, M. (2021) · Cancers · doi:10.3390/cancers13112542 · Cited by 48
“IGF-1 induced signaling pathways in myeloma cells (PI3K/AKT, MAPK, and NF-κB) that resulted in increased telomerase activity and upregulation of the antiapoptotic molecules, such as surviving cellular FADDlike IL-1β–converting enzyme (FLICE)-inhibitory protein (c-FLIP), X-linked inhibitor of apoptosis protein (XIAP),…”
BackgroundPeng, Y., Li, F., Zhang, P., Wang, X., Shen, Y., Feng, Y., Jia, Y., Zhang, R., Hu, J., & He, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117503 · Cited by 42
Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma
Akhtar, S., Ali, T. A., Faiyaz, A., Khan, O. S., Raza, S. S., Kulinski, M., Omri, H. E., Bhat, A. A., & Uddin, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145002 · Cited by 44
García-Sánchez, D., González-González, A., Alfonso-Fernández, A., Del Dujo-Gutiérrez, M., & Pérez-Campo, F. M. (2023) · World Journal of Stem Cells · doi:10.4252/wjsc.v15.i5.421 · Cited by 32
Tarte, K., Jourdan, M., Veyrune, J. L., Berberich, I., Fiol, G., Redal, N., Shaughnessy, J., & Klein, B. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04908.x · Cited by 28
“In addition, the expression of Bfl-1/A1 in malignant PC is still a matter of controversy (Mitsiades et al, 2002a,b; Jourdan et al, 2003).”
BackgroundMethod
Metadata
- Authors
- Mitsiades, C. S., Mitsiades, N., Poulaki, V., Schlossman, R., Akiyama, M., Chauhan, D., Hideshima, T., Treon, S. P., Munshi, N. C., Richardson, P. G., & Anderson, K. C.
- Venue
- Oncogene
- Published
- 2002-08-13
- Volume
- 21
- Issue
- 37
- Pages
- 5673-5683
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2024969918
- Cited by
- 464
- References
- 42
- FWCI
- 17.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.